寻找能终结阿尔茨海默病的药物。

The Search for a Drug to End Alzheimer's.

出版信息

IEEE Pulse. 2021 Mar-Apr;12(2):2-7. doi: 10.1109/MPULS.2021.3066715.

DOI:10.1109/MPULS.2021.3066715

Abstract

On November 6, 2020, researchers who have been laboring to find a drug that will treat Alzheimer's disease (AD) dialed in to a public meeting of the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee. The committee would review drug trials of Biogen's aducanumab, and conclude with a vote on the drug's safety and efficacy in treating AD. The independent advisors' decision wouldn't be the official one for aducanumab, but their vote usually mirrors the final FDA decision.

摘要

2020 年 11 月 6 日，一直致力于寻找治疗阿尔茨海默病（AD）药物的研究人员参加了美国食品和药物管理局（FDA）外周和中枢神经系统药物咨询委员会的公开会议。该委员会将审查百健公司 aducanumab 的药物试验，并对该药物治疗 AD 的安全性和有效性进行投票。独立顾问的决定不会成为 aducanumab 的官方决定，但他们的投票通常反映了最终的 FDA 决定。